Key result
Low-dose transdermal scopolamine increases HRV by ~30% vs placebo in men post-MI.
Why the study?
Low heart rate variability is associated with increased mortality after acute myocardial infarction, prompting the hypothesis that low dose transdermal scopolamine could increase heart rate variability by enhancing parasympathetic activity.
Does low dose transdermal scopolamine increase heart rate variability in male patients after acute myocardial infarction?
RCT (n=61)
Placebo-controlled
Randomized
Does low dose transdermal scopolamine increase heart rate variability in male patients after acute myocardial infarction?
Effect estimate: 26% to 35% increase above baseline
Low dose transdermal scopolamine safely increases cardiac parasympathetic activity and short-term heart rate variability after acute myocardial infarction.
No takes yet. Share an insight, caveat, or question.
May enhance vagal tone post-AMI; extends RCT evidence for scopolamine on HRV.
Vybiral et al. (1993) conducted an RCT in Acute myocardial infarction (n=61). Transdermal scopolamine vs. Matching placebo patch was evaluated on 24-h heart rate variability (time domain measures) (26% to 35% increase above baseline). Low dose transdermal scopolamine significantly increased 24-hour heart rate variability by 26% to 35% above baseline compared with placebo in male patients after acute myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: